Literature DB >> 25707764

CT-proET1 predicts pulmonary hemodynamics in Scleroderma-associated pulmonary hypertension.

Henrik Ten Freyhaus1, Daniel Dumitrescu, Sonja Schnorbach, Kai Kappert, Thomas Viethen, Martin Hellmich, Nicolas Hunzelmann, Stephan Rosenkranz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25707764     DOI： 10.1007/s00392-015-0825-4

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN： 1861-0684            Impact factor:   5.460


× No keyword cloud information.
  10 in total

1.  Changes in causes of death in systemic sclerosis, 1972-2002.

Authors:  Virginia D Steen; Thomas A Medsger
Journal:  Ann Rheum Dis       Date:  2007-02-28       Impact factor: 19.103

2.  Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma.

Authors:  Jana Papassotiriou; Nils G Morgenthaler; Joachim Struck; Christine Alonso; Andreas Bergmann
Journal:  Clin Chem       Date:  2006-04-20       Impact factor: 8.327

3.  Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension.

Authors:  Mark H Williams; Clive E Handler; Raza Akram; Colette J Smith; Clare Das; Joanna Smee; Devaki Nair; Christopher P Denton; Carol M Black; John G Coghlan
Journal:  Eur Heart J       Date:  2006-04-27       Impact factor: 29.983

4.  Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension.

Authors:  Anna Fijalkowska; Marcin Kurzyna; Adam Torbicki; Grzegorz Szewczyk; Michal Florczyk; Piotr Pruszczyk; Monika Szturmowicz
Journal:  Chest       Date:  2006-05       Impact factor: 9.410

5.  Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure.

Authors:  Alfons Gegenhuber; Joachim Struck; Benjamin Dieplinger; Werner Poelz; Richard Pacher; Nils G Morgenthaler; Andreas Bergmann; Meinhard Haltmayer; Thomas Mueller
Journal:  J Card Fail       Date:  2007-02       Impact factor: 5.712

6.  N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension.

Authors:  Hanno H Leuchte; Michal El Nounou; Juergen Christian Tuerpe; Bertram Hartmann; Rainer A Baumgartner; Michael Vogeser; Olaf Muehling; Jürgen Behr
Journal:  Chest       Date:  2007-02       Impact factor: 9.410

7.  Predicting mortality and morbidity after elective cardiac surgery using vasoactive and inflammatory biomarkers with and without the EuroSCORE model.

Authors:  Abraham Schoe; Emile F Schippers; Stefan Ebmeyer; Joachim Struck; Robert J M Klautz; Evert de Jonge; Jaap T van Dissel
Journal:  Chest       Date:  2014-11       Impact factor: 9.410

8.  Increased plasma levels of adrenomedullin in patients with pulmonary hypertension.

Authors:  M Kakishita; T Nishikimi; Y Okano; T Satoh; S Kyotani; N Nagaya; K Fukushima; N Nakanishi; S Takishita; A Miyata; K Kangawa; H Matsuo; T Kunieda
Journal:  Clin Sci (Lond)       Date:  1999-01       Impact factor: 6.124

9.  An exploratory panel of biomarkers for risk prediction in pulmonary hypertension: emerging role of CT-proET-1.

Authors:  João Silva Marques; Susana Robalo Martins; Carina Calisto; Susana Gonçalves; Ana Gomes Almeida; João Carvalho de Sousa; Fausto José Pinto; António Nunes Diogo
Journal:  J Heart Lung Transplant       Date:  2013-08-02       Impact factor: 10.247

10.  Identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-endothelin-1.

Authors:  Ewa A Jankowska; Gerasimos S Filippatos; Stephan von Haehling; Jana Papassotiriou; Nils G Morgenthaler; Mariantonietta Cicoira; Joerg C Schefold; Piotr Rozentryt; Beata Ponikowska; Wolfram Doehner; Waldemar Banasiak; Oliver Hartmann; Joachim Struck; Andreas Bergmann; Stefan D Anker; Piotr Ponikowski
Journal:  PLoS One       Date:  2011-01-17       Impact factor: 3.240
  10 in total
  1 in total

1.  Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.

Authors:  Arnica Behringer; Manuela Trappiel; Eva Maria Berghausen; Henrik Ten Freyhaus; Ernst Wellnhofer; Margarete Odenthal; Florian Blaschke; Fikret Er; Natig Gassanov; Stephan Rosenkranz; Stephan Baldus; Kai Kappert; Evren Caglayan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-01-07       Impact factor: 3.000
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.